1 / 20

NSAIDS & PPI’S: Reducing the risk

Farrukh Javid. NSAIDS & PPI’S: Reducing the risk. Why such an interesting topic?. Noticed many patients had NSAIDs on repeat rx without gastroprotection Confused about when/whom to give PPI cover to Felt like I was prescribing it by the bucketload.

will
Télécharger la présentation

NSAIDS & PPI’S: Reducing the risk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Farrukh Javid NSAIDS & PPI’S: Reducing the risk

  2. Why such an interesting topic? • Noticed many patients had NSAIDs on repeat rx without gastroprotection • Confused about when/whom to give PPI cover to • Felt like I was prescribing it by the bucketload...

  3. “Medicine is the art of entertaining the patient, as the body heals itself.” • Voltaire

  4. “A witty saying proves nothing.” • Voltaire

  5. Risks of chronic NSAID use • GI – bleeding, ulceration • Renal impairment • Cardiovascular- MI, stroke risk

  6. Risks of chronic NSAID use (2) • BNF: • Hepatic damage, alveolitis, pulmonary eosinophilia, pancreatitis, visual disturbances, Stevens-Johnson syndrome, and toxic epidermal necrolysis. • Induction of or exacerbation of colitis or Crohn’s disease. • Aseptic meningitis

  7. Guidelines • Inconclusive • Conflicting advice – who should be on PPI • Difficult to interpret – What constitutes “long term” NSAID use

  8. When offering treatment with an oral NSAID/COX-2 inhibitor, the first choice should be either a standard NSAID or a COX-2 inhibitor. In either case, these should be co-prescribed with a PPI, choosing the one with the lowest acquisition cost.

  9. The audit... • April 2011 • Total list size = 6427 • Searched for patients who: • were on NSAIDs on their repeat Rx OR had recently had more than 2 prescriptions of an NSAID on their acute list in the last 3 months • BNF 10.1 minus exceptions • AND • Not on PPI or not had one issued

  10. Initial results • 64 patients in total • Manually analysed patient records to determine whether or not the patient required gastroprotection • Common reasons for exclusion: • Not using NSAID regularly • On ranitidine/have since been put on PPI • Patient left/deceased

  11. 47 Patients remaining • Sent a letter...

  12. Round 1 • 26 patients replied to initial letter within 6 weeks – started on omeprazole • 21 patients remaining • Some patients saw a GP to discuss the medication • 4 patients declined PPI

  13. Re-audit • Repeated search end of June • 10 patients remaining • 2 patients tried PPI but c/o nausea • Re-sent (modified) letter to remaining patients • 2 patients not replied, ie-not on PPI

  14. Outcomes/Recommendations • Patient/Doctor education • Not all NSAIDs are equally risky • Highest risk: Azapropazone • Intermediate risk: piroxicam/ketoprofen /indometacin/diclofenac/naproxen • Low risk: Ibuprofen • Consider topical NSAIDs if appropriate • Use the lowest effective dose for the shortest duration of treatment

  15. Outcomes/Recommendations • Consider risk factors when prescribing: • Age, co-morbidity, CV/renal risk • Other medications, eg – aspirin, warfarin, ACE-i • Previous GI adverse effects/ulcers • Regular review of NSAID use • More frequent review if more risk factors • Consider coxibs if GI risk factors (but increase CV risk) • PPI’s aren’t risk free either!

  16. Extension of audit • Looking at patients with risk factors that are on NSAIDs. Eg: • Age • Co-morbidity • Previous GI adverse effects • Taking aspirin/warfarin/ACE-i etc. • How many patients having BP/renal function checked on regular basis

  17. Questions?

  18. References • Primary Prevention of Adverse Gastroduodenal Effects from Short-Term Use of Non-Steroidal Anti-Inflammatory Drugs by Omeprazole 20 mg in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. Dig Dis Sci (2008) 53:2059–2065 • Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology 2008;47:458–463 • Management of NSAID-Induced Gastrointestinal Toxicity: Focus on Proton Pump Inhibitors. Drugs 2009; 69 (1): 51-69 • http://bnf.org/bnf/bnf/current/60265.htm • http://www.npc.nhs.uk/rapidreview/?p=293 • http://www.npc.nhs.uk/qipp/resources/qipp_document_jan2011_version1.1_march11_final.pdf • http://www.cks.nhs.uk/nsaids_prescribing_issues/evidence/supporting_evidence/prevention_of_gi_adverse_effects • http://www.nice.org.uk/nicemedia/live/11926/39557/39557.pdf

More Related